Axon Enterprise, Inc (NASDAQ:AXON) Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. raised its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 54.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,942 shares of the biotechnology company's stock after purchasing an additional 35,699 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.13% of Axon Enterprise worth $53,090,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Capital World Investors boosted its position in Axon Enterprise by 86.4% during the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after acquiring an additional 841,772 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after purchasing an additional 812,337 shares during the period. Norges Bank acquired a new stake in shares of Axon Enterprise during the fourth quarter worth $482,081,000. GQG Partners LLC acquired a new stake in shares of Axon Enterprise during the fourth quarter worth $478,349,000. Finally, GAMMA Investing LLC grew its position in shares of Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after purchasing an additional 763,431 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on AXON shares. Bank of America raised their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Barclays raised their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Needham & Company LLC increased their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus price target of $699.55.

Axon Enterprise Stock Up 2.4%

Shares of Axon Enterprise stock opened at $803.95 on Friday. Axon Enterprise, Inc has a twelve month low of $279.02 and a twelve month high of $806.64. The stock has a market cap of $62.59 billion, a price-to-earnings ratio of 194.19, a price-to-earnings-growth ratio of 90.37 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. The company has a fifty day moving average price of $709.79 and a 200 day moving average price of $629.30.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 earnings per share. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 75 shares of the business's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $771.81, for a total value of $57,885.75. Following the transaction, the chief accounting officer now owns 15,240 shares in the company, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Joshua Isner sold 905 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the sale, the president now owns 268,735 shares of the company's stock, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,642 shares of company stock valued at $30,500,428. Corporate insiders own 4.40% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.